Oxidative stress, inflammation and treatment response in major depression

Psychoneuroendocrinology

Volumn 76, Issue , 2017, Pages 197-205

  Lindqvist, Daniel ^a,b   Dhabhar, Firdaus S ^c   James, S Jill ^d   Hough, Christina M ^a   Jain, Felipe A ^a   Bersani, F Saverio ^a,e   Reus, Victor I ^a   Verhoeven, Josine E ^a,f   Epel, Elissa S ^a   Mahan, Laura ^a   Rosser, Rebecca ^a   Wolkowitz, Owen M ^a   Mellon, Synthia H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF MIAMI   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antidepressant response; Inflammation; Major depressive disorder; Oxidative stress; Selective serotonin reuptake inhibitor

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ASCORBIC ACID; C REACTIVE PROTEIN; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TUMOR NECROSIS FACTOR;

ADULT; AGE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG DOSE INCREASE; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; INFLAMMATION; MAJOR DEPRESSION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; TREATMENT RESPONSE; BLOOD; FOLLOW UP; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); OXIDATIVE STRESS; SEROTONIN UPTAKE INHIBITORS;

EID: 85003443781     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2016.11.031     Document Type: Article

References (55)

1. Abdel-Wahab, B.A., Salama, R.H., Venlafaxine protects against stress-induced oxidative DNA damage in hippocampus during antidepressant testing in mice. Pharmacol. Biochem. Behav. 100 (2011), 59–65.
2. Behr, G.A., Moreira, J.C., Frey, B.N., Preclinical and clinical evidence of antioxidant effects of antidepressant agents: implications for the pathophysiology of major depressive disorder. Oxid. Med. Cell. Longev., 2012, 2012, 609421.
3. Bender, R., Lange, S., Adjusting for multiple testing–when and how?. J. Clin. Epidemiol. 54 (2001), 343–349.
4. Berk, M., Kapczinski, F., Andreazza, A.C., Dean, O.M., Giorlando, F., Maes, M., Yucel, M., Gama, C.S., Dodd, S., Dean, B., Magalhaes, P.V., Amminger, P., McGorry, P., Malhi, G.S., Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 35 (2011), 804–817.
5. Black, C.N., Bot, M., Scheffer, P.G., Cuijpers, P., Penninx, B.W., Is depression associated with increased oxidative stress? A systematic review and meta-analysis. Psychoneuroendocrinology 51 (2015), 164–175.
6. Blom, G., Statistical Estimates and Transformed Beta-Variables. 1958, J. Wiley & Sons; Almqvist & Wiksell, New York; Stockholm.
7. Bobo, W.V., Anglero, G.C., Jenkins, G., Hall-Flavin, D.K., Weinshilboum, R., Biernacka, J.M., Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data. Hum. Psychopharmacol. 31 (2016), 185–192.
8. Bryleva, E.Y., Brundin, L., Suicidality and activation of the kynurenine pathway of tryptophan metabolism. Curr. Top. Behav. Neurosci., 2016 (in press).
9. Chiurchiu, V., Orlacchio, A., Maccarrone, M., Is modulation of oxidative stress an answer? The state of the art of redox therapeutic actions in neurodegenerative diseases. Oxid. Med. Cell. Longev., 2016, 2016, 7909380.
10. Dalle-Donne, I., Rossi, R., Colombo, R., Giustarini, D., Milzani, A., Biomarkers of oxidative damage in human disease. Clin. Chem. 52 (2006), 601–623.
11. Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9 (2008), 46–56.
12. DellaGioia, N., Devine, L., Pittman, B., Hannestad, J., Bupropion pre-treatment of endotoxin-induced depressive symptoms. Brain Behav. Immun. 31 (2013), 197–204.
13. Dhalla, N.S., Temsah, R.M., Netticadan, T., Role of oxidative stress in cardiovascular diseases. J. Hypertens. 18 (2000), 655–673.
14. Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctot, K.L., A meta-analysis of cytokines in major depression. Biol. Psychiatry 67 (2010), 446–457.
15. Emami Ardestani, M., Zaerin, O., Role of serum interleukin 6, albumin and C-reactive protein in COPD patients. Tanaffos 14 (2015), 134–140.
16. First, M.B., Structured Clinical Interview for DSM-IV Axis I Disorders. 1997, American Psychiatric Press, Washington, DC.
17. Giannoudis, P.V., Smith, M.R., Evans, R.T., Bellamy, M.C., Guillou, P.J., Serum CRP and IL-6 levels after trauma: not predictive of septic complications in 31 patients. Acta Orthop. Scand. 69 (1998), 184–188.
18. Hamilton, M., A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960), 56–62.
19. Hickman, R.J., Khambaty, T., Stewart, J.C., C-reactive protein is elevated in atypical but not nonatypical depression: data from the National Health and Nutrition Examination survey (NHANES) 1999–2004. J. Behav. Med. 37 (2014), 621–629.
20. Hiles, S.A., Baker, A.L., de Malmanche, T., Attia, J., A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity. Brain Behav. Immun. 26 (2012), 1180–1188.
21. Hindmarch, I., Beyond the monoamine hypothesis: mechanisms, molecules and methods. Eur. Psychiatry 17:Suppl. 3 (2002), 294–299.
22. Howren, M.B., Lamkin, D.M., Suls, J., Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71 (2009), 171–186.
23. Ishii, T., Takanashi, Y., Sugita, K., Miyazawa, M., Yanagihara, R., Yasuda, K., Onouchi, H., Kawabe, N., Nakata, M., Yamamoto, Y., Hartman, P.S., Ishii, N., Endogenous reactive oxygen species cause astrocyte defects and neuronal dysfunctions in the hippocampus: a new model for aging brain. Aging Cell, 2016 (in press).
24. Jesberger, J.A., Richardson, J.S., Oxygen free radicals and brain dysfunction. Int. J. Neurosci. 57 (1991), 1–17.
25. Jimenez-Fernandez, S., Gurpegui, M., Diaz-Atienza, F., Perez-Costillas, L., Gerstenberg, M., Correll, C.U., Oxidative stress and antioxidant parameters in patients with major depressive disorder compared to healthy controls before and after antidepressant treatment: results from a meta-analysis. J. Clin. Psychiatry 76 (2015), 1658–1667.
26. Joseph, J.A., Shukitt-Hale, B., Casadesus, G., Fisher, D., Oxidative stress and inflammation in brain aging: nutritional considerations. Neurochem. Res. 30 (2005), 927–935.
27. Kadiiska, M.B., Gladen, B.C., Baird, D.D., Germolec, D., Graham, L.B., Parker, C.E., Nyska, A., Wachsman, J.T., Ames, B.N., Basu, S., Brot, N., Fitzgerald, G.A., Floyd, R.A., George, M., Heinecke, J.W., Hatch, G.E., Hensley, K., Lawson, J.A., Marnett, L.J., Morrow, J.D., Murray, D.M., Plastaras, J., Roberts, L.J., 2nd Rokach, J., Shigenaga, M.K., Sohal, R.S., Sun, J., Tice, R.R., Van Thiel, D.H., Wellner, D., Walter, P.B., Tomer, K.B., Mason, R.P., Barrett, J.C., Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?. Free Radic. Biol. Med. 38 (2005), 698–710.
28. Keaney, J.F. Jr., Larson, M.G., Vasan, R.S., Wilson, P.W., Lipinska, I., Corey, D., Massaro, J.M., Sutherland, P., Vita, J.A., Benjamin, E.J., Framingham, S., Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler. Thromb. Vasc. Biol. 23 (2003), 434–439.
29. Kelso, A., The enigma of cytokine redundancy. Immunol. Cell. Biol. 72 (1994), 97–101.
30. Kessler, R.C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K.R., Rush, A.J., Walters, E.E., Wang, P.S., The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289 (2003), 3095–3105.
31. Kotan, V.O., Sarandol, E., Kirhan, E., Ozkaya, G., Kirli, S., Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: a 24-week follow-up study. Prog. Neuropsychopharmacol. Biol. Psychiatry 35 (2011), 1284–1290.
32. Le Lay, S., Simard, G., Martinez, M.C., Andriantsitohaina, R., Oxidative stress and metabolic pathologies: from an adipocentric point of view. Oxid. Med. Cell. Longev., 2014, 2014, 908539.
33. Lindqvist, D., Mueller, S., Mellon, S.H., Su, Y., Epel, E.S., Reus, V.I., Rosser, R., Mahan, L., Mackin, R.S., Yang, T.T., Wolkowitz, O.M., Peripheral antioxidant markers are associated with total hippocampal and CA3/dentate gyrus volume in MDD and healthy controls-preliminary findings. Psychiatry Res. 224 (2014), 168–174.
34. Lindqvist, D., Wolkowitz, O.M., Mellon, S., Yehuda, R., Flory, J.D., Henn-Haase, C., Bierer, L.M., Abu-Amara, D., Coy, M., Neylan, T.C., Makotkine, I., Reus, V.I., Yan, X., Taylor, N.M., Marmar, C.R., Dhabhar, F.S., Proinflammatory milieu in combat-related PTSD is independent of depression and early life stress. Brain Behav. Immun. 42 (2014), 81–88.
35. Luca, M., Luca, A., Calandra, C., Accelerated aging in major depression: the role of nitro-oxidative stress. Oxid. Med. Cell. Longev., 2013, 2013, 230797.
36. Maes, M., Kubera, M., Leunis, J.C., The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro. Endocrinol. Lett. 29 (2008), 117–124.
37. Maes, M., An intriguing and hitherto unexplained co-occurrence: depression and chronic fatigue syndrome are manifestations of shared inflammatory, oxidative and nitrosative (IO&NS) pathways. Prog. Neuropsychopharmacol. Biol. Psychiatry 35 (2011), 784–794.
38. Margolis, S.A., Schapira, R.M., Liquid chromatographic measurement of L-ascorbic acid and D-ascorbic acid in biological samples. J. Chromatogr B.: Biomed. Sci. Appl. 690 (1997), 25–33.
39. Mellon, S.H., Wolkowitz, O.M., Schonemann, M.D., Epel, E.S., Rosser, R., Burke, H.B., Mahan, L., Reus, V.I., Stamatiou, D., Liew, C.C., Cole, S.W., Alterations in leukocyte transcriptional control pathway activity associated with major depressive disorder and antidepressant treatment. Transl. Psychiatry, 6, 2016, e821.
40. Miller, A.H., Depression and immunity: a role for T cells?. Brain Behav. Immun. 24 (2010), 1–8.
41. Milne, G.L., Yin, H., Brooks, J.D., Sanchez, S., Jackson Roberts, L., 2nd Morrow, J.D., Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol. 433 (2007), 113–126.
42. Morrow, J.D., Roberts, L.J. 2nd., Mass spectrometric quantification of F2-isoprostanes as indicators of oxidant stress. Methods Mol. Biol. 186 (2002), 57–66.
43. Ng, F., Berk, M., Dean, O., Bush, A.I., Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 11 (2008), 851–876.
44. Nicola, N.A., Cytokine pleiotropy and redundancy: a view from the receptor. Stem Cells 12:Suppl. 1 (1994), 3–12 discussion 12–14.
45. O'Connor, J.C., Lawson, M.A., Andre, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K.W., Dantzer, R., Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 14 (2009), 511–522.
46. Raison, C.L., Capuron, L., Miller, A.H., Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27 (2006), 24–31.
47. Sarandol, A., Sarandol, E., Eker, S.S., Erdinc, S., Vatansever, E., Kirli, S., Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum. Psychopharmacol. 22 (2007), 67–73.
48. Schiepers, O.J., Wichers, M.C., Maes, M., Cytokines and major depression. Prog Neuropsychopharmacol Biol. Psychiatry 29 (2005), 201–217.
49. Sheline, Y.I., Disabato, B.M., Hranilovich, J., Morris, C., D'Angelo, G., Pieper, C., Toffanin, T., Taylor, W.D., MacFall, J.R., Wilkins, C., Barch, D.M., Welsh-Bohmer, K.A., Steffens, D.C., Krishnan, R.R., Doraiswamy, P.M., Treatment course with antidepressant therapy in late-life depression. Am. J. Psychiatry 169 (2012), 1185–1193.
50. Simon, N.M., McNamara, K., Chow, C.W., Maser, R.S., Papakostas, G.I., Pollack, M.H., Nierenberg, A.A., Fava, M., Wong, K.K., A detailed examination of cytokine abnormalities in major depressive disorder. Eur. Neuropsychopharmacol. 18 (2008), 230–233.
51. Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., Cleare, A.J., Inflammation and clinical response to treatment in depression: a meta-analysis. Eur. Neuropsychopharmacol. 25 (2015), 1532–1543.
52. Uher, R., Tansey, K.E., Dew, T., Maier, W., Mors, O., Hauser, J., Dernovsek, M.Z., Henigsberg, N., Souery, D., Farmer, A., McGuffin, P., An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am. J. Psychiatry 171 (2014), 1278–1286.
53. Wu, L.L., Chiou, C.C., Chang, P.Y., Wu, J.T., Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin. Chim. Acta 339 (2004), 1–9.
54. Yilmaz, M.I., Baykal, Y., Kilic, M., Sonmez, A., Bulucu, F., Aydin, A., Sayal, A., Kocar, I.H., Effects of statins on oxidative stress. Biol. Trace Elem. Res. 98 (2004), 119–127.
55. Yirmiya, R., Endotoxin produces a depressive-like episode in rats. Brain Res. 711 (1996), 163–174.